checkAd

LOGC Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per share is fair to LogicBio shareholders.

Halper Sadeh encourages LogicBio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether LogicBio and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for LogicBio shareholders; (2) determine whether AstraZeneca is underpaying for LogicBio; and (3) disclose all material information necessary for LogicBio shareholders to adequately assess and value the merger consideration. On behalf of LogicBio shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages LogicBio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


The LogicBio Therapeutics Stock currently trades with a raise of +661,73 % to 2,11EUR on the Lang & Schwarz stock exchange.



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  136   |   |   

Schreibe Deinen Kommentar

Disclaimer

LOGC Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per share is fair to LogicBio shareholders. Halper Sadeh encourages LogicBio …

Nachrichten des Autors

421 Leser
179 Leser
143 Leser
143 Leser
115 Leser
113 Leser
113 Leser
111 Leser
108 Leser
107 Leser
421 Leser
415 Leser
235 Leser
209 Leser
209 Leser
182 Leser
180 Leser
179 Leser
166 Leser
147 Leser
1142 Leser
769 Leser
589 Leser
515 Leser
501 Leser
498 Leser
472 Leser
464 Leser
464 Leser
434 Leser
7528 Leser
2918 Leser
2431 Leser
2402 Leser
2158 Leser
2102 Leser
1787 Leser
1699 Leser
1586 Leser
1533 Leser